Age of onset in single-positive anti-GBM disease shows a distinct bimodal distribution compared to double-positive patients, according to data published in Nature.
Researchers evaluated a cohort of 180 patients, identifying 117 individuals with single-positive anti-GBM disease and 63 patients who tested double-positive for both anti-GBM antibodies and ANCA.
The first peak of onset for single-positive patients occurs between 20 and 29 years old, while the second peak emerges between 60 and 69 years old. Single-positive patients present at a significantly younger median age of 52 years old compared to a median age of 65 years old in the double-positive group.
Double-positive patients have symptoms for an average of 4.4 weeks before diagnosis, compared with 2.9 weeks for single-positive patients, Nature reported. Gross hematuria occurs more frequently among single-positive patients at 14.5 percent, versus 4.8 percent in the double-positive cohort.
Despite differences in symptom duration, initial disease severity remains comparable between both groups. Renal function parameters in non-renal replacement therapy patients show similar serum creatinine levels of 483 [IQR: 174–917] versus 552 [IQR: 213–925] micromoles per liter and estimated glomerular filtration rates of 10.1 [IQR: 4.4–32.3] versus 8.1 [IQR: 3.3–22.1] milliliters per minute per 1.73 square meters across cohorts.
Regarding serum immunological indexes, the single-positive group had higher serum complement C3 levels and lower circulating immunoglobulin G levels compared to the double-positive group. While not statistically significant, the double-positive patients generally had lower circulating anti-GBM antibodies than the single-positive patients, with a median of 389 versus 490.
| Clinical Feature | Single-Positive Patients (n=117) | Double-Positive Patients (n=63) |
|---|---|---|
| Median Age (Years) | 52 | 65 |
| Symptom Duration (Weeks) | 2.9 | 4.4 |
| Gross Hematuria (%) | 14.5% | 4.8% |
| Initial Dialysis Dependence (%) | 62.4% | 50.8% |
Initial treatment protocols, including plasma exchange, corticosteroids, and cyclophosphamide, show no significant divergence between the two patient populations. However, maintenance immunosuppression therapy at six months is administered more frequently to double-positive patients at 56.3 percent, compared to 17.8 percent for single-positive individuals.
Nature, the British weekly scientific journal founded in 1869 by Norman Lockyer and Alexander MacMillan, published the peer-reviewed research detailing these cohort findings. Operating under Springer Nature with editorial offices in London, the United States, continental Europe, and Asia, the journal maintains an acceptance rate below 8 percent for submitted papers and, as of 2012, reported an online readership of about three million unique readers per month.
Renal function recovery rates among patients who begin initial visits requiring dialysis differ notably over the long term. The proportion of dialysis-dependent double-positive patients who recover renal function and survive for one year reaches 29.6 percent, compared to 1.8 percent in the single-positive group.
Related reading